Document is current
Any future updates will be listed below
-
Authors
Vasaikar, Suhas
Tsipras, Giorgos
Landázuri, Natalia
Costa, Helena
Wilhelmi, Vanessa
Scicluna, Patrick
Cui, Huanhuan L.
Mohammad, Abdul-Aleem
Davoudi, Belghis
Shang, Mingmei
Ananthaseshan, Sharan
Strååt, Klas
Stragliotto, Giuseppe
Rahbar, Afsar
Wong, Kum Thong
Tegner, Jesper
Yaiw, Koon-Chu http://orcid.org/0000-0001-5329-1815
Söderberg-Naucler, Cecilia
-
Funding
Funding for this research was provided by:
Sten A Olssons Foundation for Research and Culture
Familjen Erling-Perssons Stiftelse
Torsten Söderbergs Stiftelse
BILTEMA Foundation
lngaBritt and Arne Lundbergs Foundation
Stichting af Jochnick Foundation
Jane and Dan Olssons Research Foundation,
Nexttobe
Barncancerfonden
Swedish Cancer Foundation
Swedish Medical Research Council
Thematic Cardiovascular Research Center and Stockholm County Council
the Swedish Heart-Lung Foundation
VINNOVA-BIO-X and Medivir AB
Cure cancer /Bota Cancer
-
More Information
Article History
Received: 30 December 2016
Accepted: 22 January 2018
First Online: 6 February 2018
Ethics approval and consent to participate
: The use of patient materials was approved by the Ethics Committee at the Karolinska Institutet and by the Medical Ethics Committee, University of Malaya Medical Center, Malaysia, and conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: A patent application for use of ETBR inhibitors in prevention and treatment of HCMV infection and CMV-related pathologies such as cardiovascular diseases and cancer has been filed (to CSN and KCY).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
